NCT04706767

Brief Summary

BACKGROUND: Some studies have revealed that intravenous (IV) lidocaine or dexmedetomidine might improve the quality of recovery undergoing laparoscopic surgery. The investigators investigated whether co-administration lidocaine and dexmedetomidine could better improve the the quality of recovery after laparoscopic total hysterectomy. METHODS: One hundred and forty-four women with elective laparoscopic total hysterectomy were randomly divided into four groups: Patients in group L received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close the pneumoperitoneum. Patients in group D received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close the pneumoperitoneum. Patients in group LD received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close the pneumoperitoneum, respectively. Patients in group C received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close the pneumoperitoneum. Primary outcome was the quality of recovery (QoR-40) at 1 day prior to sugery, 1 day after sugery, and 2 days after sugery. The secondary outcomes included perioperative remifentanil consumption, postoperative VAS scores, the incidence of postoperative nausea and vomiting, postoperative rescue analgesics and anti-emetics, recovery time, extubation time, and Ramsay sedation scale at 5 min, 10min, 30 min, 60 min after extubation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
160

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 11, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 13, 2021

Completed
15 days until next milestone

Study Start

First participant enrolled

January 28, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 25, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 25, 2021

Completed
Last Updated

March 10, 2022

Status Verified

March 1, 2022

Enrollment Period

5 months

First QC Date

January 11, 2021

Last Update Submit

March 8, 2022

Conditions

Keywords

LidocaineDexmedetomidineQuality of recovery

Outcome Measures

Primary Outcomes (1)

  • Quality of recovery scores(QoR-40)

    Our primary outcome was Quality of recovery scores(QoR-40) 1 day after operation

    1 day after operation

Secondary Outcomes (7)

  • Intraoperative remifentanil total dose

    Intraoperative

  • Recovery time

    Immediately after the surgery

  • Extubation time

    Immediately after the surgery

  • Pain visual analogue scale scores

    The first 24 hours after operation

  • PONV scores

    The first 24 hours after operation

  • +2 more secondary outcomes

Study Arms (4)

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of Recovery

EXPERIMENTAL
Drug: Co-administration Lidocaine and DexmedetomidineDrug: Dexmedetomidine infusionDrug: Lidocaine infusionDrug: Saline infusion

Effect of Dexmedetomidine infusion on Quality of Recovery

EXPERIMENTAL
Drug: Co-administration Lidocaine and DexmedetomidineDrug: Dexmedetomidine infusionDrug: Lidocaine infusionDrug: Saline infusion

Effect of Lidocaine infusion on Quality of Recovery

EXPERIMENTAL
Drug: Co-administration Lidocaine and DexmedetomidineDrug: Dexmedetomidine infusionDrug: Lidocaine infusionDrug: Saline infusion

Effect of saline infusion on Quality of Recovery

EXPERIMENTAL
Drug: Co-administration Lidocaine and DexmedetomidineDrug: Dexmedetomidine infusionDrug: Lidocaine infusionDrug: Saline infusion

Interventions

Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg) and dexmedetomidine (0.5 µg/kg) over 10 min before the induction of anesthesia, and then lidocaine and dexmedetomidine were infused at a rate of 1.5 mg/kg/h and 0.4 µg/kg/h until close of the pneumoperitoneum, respectively.

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of RecoveryEffect of Dexmedetomidine infusion on Quality of RecoveryEffect of Lidocaine infusion on Quality of RecoveryEffect of saline infusion on Quality of Recovery

Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until close of the pneumoperitoneum.

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of RecoveryEffect of Dexmedetomidine infusion on Quality of RecoveryEffect of Lidocaine infusion on Quality of RecoveryEffect of saline infusion on Quality of Recovery

Patients received a bolus infusion of lidocaine (2%; 1.5 mg/kg over 10 min before the induction of anesthesia), and then lidocaine was infused at a rate of 1.5 mg/kg/h until close of the pneumoperitoneum.

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of RecoveryEffect of Dexmedetomidine infusion on Quality of RecoveryEffect of Lidocaine infusion on Quality of RecoveryEffect of saline infusion on Quality of Recovery

Patients received the same volume of normal saline 10 min before the induction of anesthesia, and then normal saline (0.9%) was continuously infused in an equal volume until close of the pneumoperitoneum.

Effect of Co-administration Lidocaine and Dexmedetomidine on Quality of RecoveryEffect of Dexmedetomidine infusion on Quality of RecoveryEffect of Lidocaine infusion on Quality of RecoveryEffect of saline infusion on Quality of Recovery

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • American Society of Anesthesiologists (ASA) physical statusⅠand Ⅱ
  • Scheduled for elective laparoscopic total hysterectomy

You may not qualify if:

  • History of allergy to local anesthetics
  • BMI\>30
  • Severe respiratory disease
  • Renal or hepatic insufficiency
  • History of preoperative opioids medication and psychiatric
  • preoperative bradycardia
  • preoperative atrioventricular block

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anqing Hospital Anesthesiology

Anqing, Anhui, 246000, China

Location

MeSH Terms

Interventions

Dexmedetomidine

Intervention Hierarchy (Ancestors)

ImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 11, 2021

First Posted

January 13, 2021

Study Start

January 28, 2021

Primary Completion

June 25, 2021

Study Completion

June 25, 2021

Last Updated

March 10, 2022

Record last verified: 2022-03

Locations